Silent cerebral infarct (SCI) is the most common form of neurologic disease in children with sickle cell anemia (SCA). SCI is defined as abnormal magnetic resonance imaging (MRI) of the brain in the setting of a normal neurologic examination without a history or physical findings associated with an overt stroke. SCI occurs in 27% of this population before their sixth, and 37% by their 14th birthdays. In adults with SCA, the clinical history of SCI is poorly defined, although recent evidence suggests that they too may have ongoing risk of progressive injury. Risk factors for SCI include male sex, lower baseline hemoglobin concentration, higher baseline systolic blood pressure, and previous seizures. Specific morbidity associated with SCI includes a decrement in general intellectual abilities, poor academic achievement, progression to overt stroke, and progressive SCI. In addition, children with previous stroke continue to have both overt strokes and new SCI despite receiving regular blood transfusion therapy for secondary stroke prevention. Studies that only include overt stroke as a measure of CNS injury significantly underestimate the total cerebral injury burden in this population. In this review, we describe the epidemiology, natural history, morbidity, medical management, and potential therapeutic options for SCI in SCA.

One of the most devastating medical complications of sickle cell anemia (SCA) is cerebral injury, which limits the full potential of the developing child and adult. The most common neurologic injury in SCA is silent cerebral infarct (SCI). Although there are few studies, SCI occurs in approximately one-quarter of children with SCA before their sixth birthday1  and approximately one-third before their 14th birthday.2  The first evidence that SCI had clinical significance was published in a cross-sectional computed tomography (CT) scan study of 25 patients. Five had cerebral infarcts but only 4 had a focal neurologic deficit (overt stroke).3  The investigators referred to the fifth patient as having a covert stroke,3  a term also used by others.4  The term SCI or silent stroke has gained widespread use to describe this condition because the Cooperative Study of Sickle Cell Disease (CSSCD) used standard clinical magnetic resonance imaging (MRI) to define the radiologic parameters.5  Subsequently, only a few studies of SCI have been completed. Until recently, the clinical importance of identifying SCI did not seem to justify the expense of MRI requiring sedation or anesthesia in preschool children, particularly in the absence of an effective intervention. Despite being the most common type of cerebral injury among children and adults with SCA, relatively little is known about the cause and optimal therapy of SCI. We will review the current literature on definition, epidemiology, natural history, clinical significance, medical management, and potential therapeutic options for the treatment of SCI in SCA.

The largest longitudinal cohort study to address the prevalence and incidence of SCI in children with SCA was the CSSCD, an observational study of children identified as infants and followed closely over the subsequent decade, which used MRI of the brain to detect abnormally increased T2-weighted signal intensity on multiple views (Figures 1 and 2) in children without current focal neurologic deficits as assessed by a hematologist. Previous neurologic history other than seizures, for example, coma, dizziness, ataxia, or transient focal weakness, was not explored. Hematologists may have discounted subtle neurologic findings that may have classified as abnormal and suggesting a prior overt stroke if reviewed by neurologists.6  The more precise definition used by Casella et al7  in The Silent Cerebral Infarct Trial (SIT Trial)7,8  included a MRI lesion measuring at least 3 mm in greatest linear dimension, visible in at least 2 planes of T2-weighted images (axial and coronal; Figure 2B-C). The SIT Trial definition excluded prior seizures and required no current focal neurologic deficit that could be explained by the anatomic location of the presumed SCI. Thus, individuals could have a focal neurologic examination, for example, compatible with a peripheral neuropathy, but would still meet the definition of SCI if the location of the infarct would not account for the neurologic deficit.

Figure 1

MRI in sickle cell disease. Coronal T1-weighted MRI (A,E) and axial T2-weighted MRI (B-D,F-H) in patients with homozygous SCA. (A-C) Normal MRI in a 19-year-old man with homozygous SCA. (D) Three years later, there is no change. (E-G) Silent infarction (arrows) in the frontal white matter and basal ganglia in a 15-year-old girl with cognitive problems affecting school performance but no acute neurologic presentation. (H) Three years later she has further infarcts with evidence of mild generalized atrophy and had a transient right hemiparesis as well as developing signs of a diplegia.

Figure 1

MRI in sickle cell disease. Coronal T1-weighted MRI (A,E) and axial T2-weighted MRI (B-D,F-H) in patients with homozygous SCA. (A-C) Normal MRI in a 19-year-old man with homozygous SCA. (D) Three years later, there is no change. (E-G) Silent infarction (arrows) in the frontal white matter and basal ganglia in a 15-year-old girl with cognitive problems affecting school performance but no acute neurologic presentation. (H) Three years later she has further infarcts with evidence of mild generalized atrophy and had a transient right hemiparesis as well as developing signs of a diplegia.

Close modal
Figure 2

MRI in sickle cell disease. (A) Coronal T1-weighted MRI, (B) coronal T2-weighted MRI, and (C-H) axial T2-weighted MRI in patients with homozygous SCA. (A-C) Silent cerebral infarction (white arrows) in the parietal white matter in a 10-year-old girl with headache. (D) Three years later, there is progressive atrophy on MRI in the context of intermittent ataxia and squint. (E-H) Four cases associated with acute illness. (E) Silent cerebral infarction (black arrows) in the watershed regions between the anterior, middle, and posterior regions, including the deep white matter, in a patient who had previously had posterior reversible encephalopathy syndrome in the context of cyclosporine treatment for nephrotic syndrome. (F) Bilateral watershed infarction in a child who had seizures in the context of a facial infection. Motor examination was normal but his IQ was reduced by 30 points compared with premorbid testing. (G) Encephalomalacia after sagittal sinus thrombosis secondary to pneumococcal meningitis. (H) Occipital infarction after acute chest crisis. A homonymous visual field defect was detected after the infarct was noted on MRI.

Figure 2

MRI in sickle cell disease. (A) Coronal T1-weighted MRI, (B) coronal T2-weighted MRI, and (C-H) axial T2-weighted MRI in patients with homozygous SCA. (A-C) Silent cerebral infarction (white arrows) in the parietal white matter in a 10-year-old girl with headache. (D) Three years later, there is progressive atrophy on MRI in the context of intermittent ataxia and squint. (E-H) Four cases associated with acute illness. (E) Silent cerebral infarction (black arrows) in the watershed regions between the anterior, middle, and posterior regions, including the deep white matter, in a patient who had previously had posterior reversible encephalopathy syndrome in the context of cyclosporine treatment for nephrotic syndrome. (F) Bilateral watershed infarction in a child who had seizures in the context of a facial infection. Motor examination was normal but his IQ was reduced by 30 points compared with premorbid testing. (G) Encephalomalacia after sagittal sinus thrombosis secondary to pneumococcal meningitis. (H) Occipital infarction after acute chest crisis. A homonymous visual field defect was detected after the infarct was noted on MRI.

Close modal

In the first systematic study of SCI in adults with SCA, Vichinsky et al used a definition of a minimum of 5 mm signal hyperintensity in the T2-weighted image,9  but to be included, lesions also had to show corresponding hypointensity on the T1-weighted image (Figures 1E, 2A). Normal adults typically accumulate T2 hyperintensities as they age, but children do not. This more restrictive definition of SCI and the distinction from encephalomalacia and atrophy (Figures 1H, 2D-H) parallels the descriptions used in general populations of asymptomatic elderly adults with SCI.10 

In addition to the varying definitions of SCI, lesion detection is dependent on the magnetic resonance (MR) technique (fluid attenuation inversion recovery [FLAIR] or diffusion-weighted imaging [DWI], see Figure 3, vs traditional T2-weighted images), the slice thickness,11  and the magnetic field strength. As further advances in imaging are made and medical centers transition from 1.5 Tesla to 3.0 Tesla magnets, more individuals with SCA will be detected with SCI, and quantitative techniques are likely to detect subtle abnormality in those without SCI on T2-weighted MRI.12,13  Use of the greater magnet strength will most likely have an impact on measures of incidence and prevalence of SCI, especially in longitudinal studies and CNS-related clinical trials. Thus, investigators must consider the anticipated change in the magnetic strength of the scanner over time when conducting a longitudinal study.

Figure 3

A 10-year-old boy with sickle cell disease and history of acute chest syndrome now presents with pain crisis. MRI of the brain was requested for episodic slurred speech. Axial FLAIR MR image (left) and DWI (middle) illustrate many of the manifestations of SCD in the brain. The arrowheads on the FLAIR image point out areas of old (silent) infarctions in the white matter of the centrum semiovale on the right and at the posterior aspect of the left superior frontal gyrus. The DWI shows an additional area of signal abnormality in the anterior aspect of the right superior frontal gyrus, representing a recent infarction. In addition, there is atrophy of the left cerebral hemisphere, which is seen in the setting of sickle cell–associated vasculopathy manifest by nonvisualization of the left middle cerebral artery by MRA (arrows on the right image). The MRA also shows subtle collaterals (moyamoya vessels) in the lenticulostriate distribution on the left (arrowhead).

Figure 3

A 10-year-old boy with sickle cell disease and history of acute chest syndrome now presents with pain crisis. MRI of the brain was requested for episodic slurred speech. Axial FLAIR MR image (left) and DWI (middle) illustrate many of the manifestations of SCD in the brain. The arrowheads on the FLAIR image point out areas of old (silent) infarctions in the white matter of the centrum semiovale on the right and at the posterior aspect of the left superior frontal gyrus. The DWI shows an additional area of signal abnormality in the anterior aspect of the right superior frontal gyrus, representing a recent infarction. In addition, there is atrophy of the left cerebral hemisphere, which is seen in the setting of sickle cell–associated vasculopathy manifest by nonvisualization of the left middle cerebral artery by MRA (arrows on the right image). The MRA also shows subtle collaterals (moyamoya vessels) in the lenticulostriate distribution on the left (arrowhead).

Close modal

Strict guidelines for radiographic assessment of SCI require the ability to distinguish SCI from acute and chronic mimics of SCI (Figure 4). Because of the possibility of misclassification of a diagnosis of SCI when a new lesion is suspected, a dialogue between the neuroradiologist, neurologist, and hematologist should occur so both the clinical history and differential diagnoses can be carefully considered.

Figure 4

Differential diagnosis of silent infarction (images from patients without SCA). (A) Mimics of SCI: periventricular leukomalacia (PVL). A 20-month-old boy with cerebral palsy characterized by spastic diplegia. Axial FLAIR MR images illustrate classic findings of PVL. The image on the left is at the level of the centrum semiovale and demonstrates bilateral hyperintensities in the parietal lobe white matter. This appearance of the white matter overlaps with the presentation of SCI. The image on the right at the level of the basal ganglia illustrates dysmorphic lateral ventricles, thinning of the periventricular white matter and periventricular signal hyperintensity in a predominantly posterior distribution. Taken together, the images are consistent with the diagnosis of PVL in the setting of prematurity and cerebral palsy rather than SCI. (B) Terminal zones of myelination. A 2-year-old boy with a normal MRI of the brain. The Axial FLAIR MR image (left) shows ill-defined hyperintensity bilaterally in the deep white matter adjacent to the atria of the lateral ventricles (arrows). The T2-weighted image on the right illustrates that there are well-defined linear perivascular spaces (arrowheads) traversing the area of vague hyperintensity. This combination of findings is classic for the terminal zones of myelination, the last areas of the deep white matter to myelinate and displace free water. The terminal zones of myelination remain prominent through the second year of life and become progressively less conspicuous over time. They may be visible into the middle of the first decade of life. (C) Virchow-Robin spaces. A 12-year-old boy withT2-weighted (left) and Axial FLAIR (right) MR images with a normal MRI. The T2-weighted images reveal multiple punctuate white matter hyperintensities that suppresses on FLAIR indicating that the hyperintensities are indistinguishable from cerebrospinal fluid. The fluid attenuation feature of the FLAIR image helps to differentiate perivascular (Virchow-Robin) spaces from SCI. The arrows illustrate another feature of perivascular spaces which is that they appear linear when running within the slice. (D) Posterior reversible encephalopathy syndrome (PRES). A 14-year-old girl with altered mental status and seizures. Axial FLAIR MR images demonstrate hyperintensities bilaterally in the subcortical white matter and overlying cortex with predominant subcortical involvement. The distribution of the signal abnormalities is predominantly posterior and peripheral, a typical distribution for PRES. In contradistinction, SCIs favor the deep white matter of the frontal lobes. Nevertheless, clinical context is the key to differentiating PRES from SCIs. This is especially challenging in patients with SCD because they are prone to development of PRES and SCI. (E) Acute disseminated encephalomyelitis (ADEM). A 5-year-old boy with fever and headache. Axial FLAIR MR images demonstrate patchy, bilateral hyperintensities in the white matter of the centrum semiovale and corona radiata (arrows). Although the image on the left could be confused for SCI in the frontal border zone distribution, the middle and right image show subcortical and patchy hyperintensities that would be atypical in location, size, and lesion definition for SCI. The clinical information is the key to distinguishing lesions of ADEM from SCI.

Figure 4

Differential diagnosis of silent infarction (images from patients without SCA). (A) Mimics of SCI: periventricular leukomalacia (PVL). A 20-month-old boy with cerebral palsy characterized by spastic diplegia. Axial FLAIR MR images illustrate classic findings of PVL. The image on the left is at the level of the centrum semiovale and demonstrates bilateral hyperintensities in the parietal lobe white matter. This appearance of the white matter overlaps with the presentation of SCI. The image on the right at the level of the basal ganglia illustrates dysmorphic lateral ventricles, thinning of the periventricular white matter and periventricular signal hyperintensity in a predominantly posterior distribution. Taken together, the images are consistent with the diagnosis of PVL in the setting of prematurity and cerebral palsy rather than SCI. (B) Terminal zones of myelination. A 2-year-old boy with a normal MRI of the brain. The Axial FLAIR MR image (left) shows ill-defined hyperintensity bilaterally in the deep white matter adjacent to the atria of the lateral ventricles (arrows). The T2-weighted image on the right illustrates that there are well-defined linear perivascular spaces (arrowheads) traversing the area of vague hyperintensity. This combination of findings is classic for the terminal zones of myelination, the last areas of the deep white matter to myelinate and displace free water. The terminal zones of myelination remain prominent through the second year of life and become progressively less conspicuous over time. They may be visible into the middle of the first decade of life. (C) Virchow-Robin spaces. A 12-year-old boy withT2-weighted (left) and Axial FLAIR (right) MR images with a normal MRI. The T2-weighted images reveal multiple punctuate white matter hyperintensities that suppresses on FLAIR indicating that the hyperintensities are indistinguishable from cerebrospinal fluid. The fluid attenuation feature of the FLAIR image helps to differentiate perivascular (Virchow-Robin) spaces from SCI. The arrows illustrate another feature of perivascular spaces which is that they appear linear when running within the slice. (D) Posterior reversible encephalopathy syndrome (PRES). A 14-year-old girl with altered mental status and seizures. Axial FLAIR MR images demonstrate hyperintensities bilaterally in the subcortical white matter and overlying cortex with predominant subcortical involvement. The distribution of the signal abnormalities is predominantly posterior and peripheral, a typical distribution for PRES. In contradistinction, SCIs favor the deep white matter of the frontal lobes. Nevertheless, clinical context is the key to differentiating PRES from SCIs. This is especially challenging in patients with SCD because they are prone to development of PRES and SCI. (E) Acute disseminated encephalomyelitis (ADEM). A 5-year-old boy with fever and headache. Axial FLAIR MR images demonstrate patchy, bilateral hyperintensities in the white matter of the centrum semiovale and corona radiata (arrows). Although the image on the left could be confused for SCI in the frontal border zone distribution, the middle and right image show subcortical and patchy hyperintensities that would be atypical in location, size, and lesion definition for SCI. The clinical information is the key to distinguishing lesions of ADEM from SCI.

Close modal

As is required by this definition, children with SCI do not have any obvious evidence of symptoms, other than perhaps academic or behavioral difficulties. Quite often, the presence of SCI is detected when the child presents with subtle neurologic findings prompting a brain MRI. The neuroradiologist may identify additional previous infarcts and distinguish an acute cerebral infarct from a previously unknown SCI (Figure 3A). A focal DWI hyperintensity indicates an ischemic injury within the last 8 to 10 days14  (Figure 3B), while the presence of brain atrophy suggests a chronic process.

As part of the protocol for the observational CSSCD cohort, the leadership group added serial surveillance MRI scans of the brain of children beginning at 6 years of age. A total of 266 children with SCA hemoglobin SS (HbSS) completed both a MRI of the brain and a battery of age-appropriate tests of cognitive function. The average age at initial scan was 8.3 years with each child having at least 1 follow-up scan at a mean of 12.1 years of age. The mean interval between first and follow-up studies was ∼ 2 years. In this cohort, the prevalence of SCI at baseline was 21.2%.15  SCIs commonly differ in size and location compared with overt strokes. Whereas overt strokes are typically located in both cortex and deep white matter,16  SCI in the CSSCD typically occurred in the deep white matter of the frontal (81%; Figure 1E-F) or parietal (45%) lobes (Figure 2A-D), followed in frequency by the basal ganglia (Figure 1G-H) or thalamus (16%) and the temporal lobes (9%).15  Similar observations were reported for an unselected cohort of 132 children with SCA in Créteil, France undergoing brain MRI as part of routine medical care2  and in other studies.4,5,17,18  SCI in SCA are typically smaller in size compared with overt strokes. In the CSSCD participants, 83% of the children with overt strokes, but only 16% of those with SCI, had lesions that were at least 1.5 cm.15 

The CSSCD results supported early observations that the presence of SCI is a risk factor for additional neurologic injury,19  with a higher risk of both clinical stroke (14-fold), and progressive silent infarction. Approximately 25% of the children with SCI, but only 2.5% of the children without SCI, had new and/or enlarging lesions on follow-up MRI scan. The incidence rates of new or more extensive SCI were 1.0 and 7.0 events per 100 patient-years, respectively, for children with or without preexisting SCI.15  SCI is most common in patients with hemoglobin SS but may also be identified in individuals with heterozygous genotypes including sickle β-thalassemia and hemoglobin SC (HbSC) disease. Approximately 3% to 38% of patients with sickle β-thalassemia,17,18,20,21  and 5% to 31% of those with HbSC disease,15,22  will have SCI. However, limited sample size allows no significant inferences about the rate of progression or potential benefit of therapy.

One of the greatest limitations in defining the epidemiology of SCI is the lack of longitudinal studies looking at incidence rate in different age groups. Existing studies do not fully address when SCI first occur in young children or whether the incidence of SCI falls in adolescents. Both the CSSCD and the French cohorts included children who were older than 6 years of age; thus, the youngest age at which SCI occurred in these 2 studies could not be determined. Three small studies have provided some estimates as to when SCI may start to occur. In a single-center study, 39 children with SCA with no history of a stroke underwent MRI between 7 and 48 months of age23 ; 4, including all 3 with a history of seizures, had SCI. In the second study, a multicenter phase 3 study (BABY HUG), MRI scans were performed in 23 infants with SCA at an average age of 13.7 months; 3 (13%) had SCI.24  In the third study, as part of routine medical care in children before their sixth birthday, 27.7% (18 of 65) of the asymptomatic children with SCA undergoing MRI had an SCI.1 In the French study, the incidence of SCI was 28.2% by age 8 years of age and 37.4% by age 14 years of age,2  suggesting absence of an incidence plateau (Figure 5), providing one of the reasons for current and future secondary and primary SCI prevention trials.

Figure 5

Prevalence of SCI with 95% CIs plotted against age from 4 studies.1,2,23,24 

Figure 5

Prevalence of SCI with 95% CIs plotted against age from 4 studies.1,2,23,24 

Close modal

Solid estimates of the prevalence of SCI in adults with SCA are limited by both the number of studies and study participants within and across studies. In the first longitudinal study published among patients with SCI, Kugler et al enrolled 16 individuals with SCA, but no history of stroke or transient neurologic events and normal neurologic examination, to undergo MRI of the brain at a mean age of 20 years.19  The primary aim of this study was to determine the predictive value of SCI as a risk factor for clinically apparent strokes. Patients were followed for a mean of 3.7 years. Eight (50%) had SCI, of whom 4 (25% of the total) had progressive abnormalities on MRI, with 3 developing focal neurologic deficits. In the 8 patients with normal brain MRI, there was no evidence of progression on MRI or clinically. Although not a focus, this study also found that the majority of the patients had significant deficits on cognitive testing regardless of the presence of SCI.19 

In another study of 50 adults, including 4 with overt stroke, Silva et al found that leukoencephalopathy was the most common abnormality (48%),25  followed by atrophy (28%; Figures 1H, 2D), encephalomalacia (6%; Figure 2F-H), and lacunes (Figure 1E-H; 4%). Vichinsky et al completed brain MRI in adults with SCA as an initial component of a randomized trial.9  Entry into the study required that the participants had a baseline hemoglobin concentration below 10 g/dL without any history of stroke or focal neurologic deficits, known brain imaging abnormalities, serious cognitive impairment, or evidence of depression. Nevertheless, in this group of highly selected adults with SCA, SCI, referred to as lacunar infarction, was present in 13% of the surveillance MRIs compared with 2% of the ethnic and age-matched controls without SCA. In contrast, white matter lesions occurred in 15% of individuals with SCA and 7% of controls, atrophy was seen in 23% of patients and 16% of controls, and a cortical infarct was detected in one individual with SCA and one control. The difference in SCI prevalence compared with the published pediatric cohorts may be related to either (1) the highly selected group of well-functioning adults with SCA or (2) a subtle, but important, variation in the definition of SCI, related either to the difference in minimum size (5 mm vs 3 mm) or to the requirement for T1 hypointensity, as well as T2 hyperintensity in the adult study. A longitudinal study that includes children, adolescents and adults with SCA is required to determine the true natural history and sequelae of SCI. Based on the high prevalence of SCI in adults with SCA, screening MRI of the brain may be considered standard care, despite the lack of evidence-based therapy, because detection of SCI may help facilitate employment or vocational options along with realistic expectations for the management of a complex chronic illness. Ultimately, better data are required to understand the clinical course and relevance of SCI in adults with SCA.

Children with SCI have lower cognitive test scores compared with children with a normal MRI of the brain. Poorer global intellectual function17,22,26-28  has been reported in several studies, with function below the average range for the general population, but better than that of children with overt strokes. In a summary of global intelligence quotient in children with SCA and controls, Hogan et al graphically displayed data from multiple studies that included the Full Scale IQ (FSIQ) in controls without SCA, children with SCA with or without SCI, and children with SCA and overt stroke.29  The gradient in FSIQ demonstrated the following consistent pattern: ethnically matched control children without SCA had a mean FSIQ greater than children with SCA and without SCI, who in turn had a FSIQ greater than those with SCI and covert and overt strokes (Figure 6).29  The severity of the chronic anemia,9,17  and other factors such as the home environment, are additional factors to consider when assessing the impact of SCI on cognition in SCI cognitive outcome.

Figure 6

Mean Wechsler FSIQ scores obtained from children with SCD and sibling controls as reported in 8 studies. The horizontal black line represents the mean value for each category of children. FSIQ scores have a mean of 100 (SD 15). Scores above 80 are within the average range according to Wechsler classification.27  (A) Armstrong et al22  (Normal MRI, n = 105; Silent Infarct, n = 21; Clinical History of Stroke, n = 9; age range, 6-12 years). (B) Steen et al33  (Historical Control Data, n = 30; Normal cMRI, n = 12; Abnormal cMRI, n = 10; mean age, 10 years; SD, 3 years). (C) Watkins et al4  (Control, n = 15; SCD/nm, n = 15; Asymptomatic, n = 4; Symptomatic, n = 5; age range, 5-16 years). (D) Bernaudin et al17  (Siblings, n = 76; Normal MRI, n = 104; Silent Stroke, n = 17; With (Overt) Stroke, n = 11; age range, 5-15 years). (E) Brown et al31  (no cerebrovascular accident [CVA], n = 30; Silent, n = 11; CVA, n = 22; age range, 6-17 years). (F) Wang et al28  (Normal MRI, n = 122; Silent Infarct, n = 43; Stroke, n = 20; age range, 6-18 years). (G) Thompson et al64  (First Visit: Normal, n = 93; Silent Infarct, n = 29; Stroke, n = 6; age range, 5-15 years). (H) Steen et al65  (African-American Controls, n = 30; Patients, n = 30; mean age, 10 years; SD, 2.9 years).

Figure 6

Mean Wechsler FSIQ scores obtained from children with SCD and sibling controls as reported in 8 studies. The horizontal black line represents the mean value for each category of children. FSIQ scores have a mean of 100 (SD 15). Scores above 80 are within the average range according to Wechsler classification.27  (A) Armstrong et al22  (Normal MRI, n = 105; Silent Infarct, n = 21; Clinical History of Stroke, n = 9; age range, 6-12 years). (B) Steen et al33  (Historical Control Data, n = 30; Normal cMRI, n = 12; Abnormal cMRI, n = 10; mean age, 10 years; SD, 3 years). (C) Watkins et al4  (Control, n = 15; SCD/nm, n = 15; Asymptomatic, n = 4; Symptomatic, n = 5; age range, 5-16 years). (D) Bernaudin et al17  (Siblings, n = 76; Normal MRI, n = 104; Silent Stroke, n = 17; With (Overt) Stroke, n = 11; age range, 5-15 years). (E) Brown et al31  (no cerebrovascular accident [CVA], n = 30; Silent, n = 11; CVA, n = 22; age range, 6-17 years). (F) Wang et al28  (Normal MRI, n = 122; Silent Infarct, n = 43; Stroke, n = 20; age range, 6-18 years). (G) Thompson et al64  (First Visit: Normal, n = 93; Silent Infarct, n = 29; Stroke, n = 6; age range, 5-15 years). (H) Steen et al65  (African-American Controls, n = 30; Patients, n = 30; mean age, 10 years; SD, 2.9 years).

Close modal

Specific areas of deficit have been associated with SCI, including executive functions like selective attention, card sorting, working memory, and processing speed,4,30-32  visual motor speed and coordination,4,22  vocabulary,17,22,28,33  visual memory,34  and abstract reasoning and verbal comprehension.17,35  As a consequence of these specific deficits, academic achievement in math and reading are also affected, with one study reporting that the 35% of children with SCA and SCI had twice the chance of academic difficulties as those without SCI.26 

Using the definition from the CSSCD, along with a negative neurologic examination by a pediatric neurologist, the group at Washington University demonstrated that lesion location correlated with deficits attributable to the corresponding cognitive domain,36  that the volume of the SCI was associated with the magnitude of cognitive deficit,37,38  and that the presence of SCI was associated with poor academic attainment compared with controls.27  Together these data clearly demonstrate that SCI are associated with a specific cognitive profile correlating with their distribution in the frontal lobe, and are associated with cognitive deficits and academic difficulties compared with children with SCA but normal MRI as well as unaffected siblings (Figures 6 and 7).

Figure 7

The proportion of students with SCA with and without SCIs and sibling controls that have either failed a grade or received special services.26 

Figure 7

The proportion of students with SCA with and without SCIs and sibling controls that have either failed a grade or received special services.26 

Close modal

Large infarcts in an arterial territory, or in the border zones between anterior and middle cerebral arteries, have been described in patients dying after a documented overt stroke,39,40  in association with endothelial hyperplasia, fibroblastic reaction, hyalinization and fragmentation of the internal elastic lamina, and thrombi in large and small vessels.39  There are no autopsy studies from the neuroimaging era that have focused specifically on the pathology of subclinical brain damage, such as SCI, in SCA. Pathologies inferred to account for the typical small necrotic lesions in the border between the cortex and the subcortical white matter include acute demyelination41  and venous sinus thrombosis,39  as well as disease of the small arteries and arterioles.

Only a few studies have specifically evaluated risk factors for SCI in SCA. The CSSCD compared 42 children with SCA and SCI with 188 children with SCA but without SCI. In a multivariable logistic regression, clinical risk factors associated with SCI included a history of seizures, low pain event rate, elevated white blood cell count, and the SEN βS globin gene haplotype.6  Two significant limitations should be considered, however, when interpreting these results. First, the CSSCD research team later updated their results from this same cohort and acknowledged that their adjudication process for SCI improved.15  Second, the sample size of children with SCI was relatively small, limiting the ability to detect small differences and resulting in odds ratios (ORs) with large confidence intervals (CIs). In a single-center study of the risk factors for SCI in a longitudinal prospective cohort,2  the only independent risk factor for SCI was baseline low hemoglobin level.

In the SIT Trial cross-sectional study, in which participants with epilepsy, as well as those with abnormal transcranial Doppler (TCD), were excluded, 814 children with SCI-like lesions were examined by a pediatric neurologist to confirm that the cerebral lesions were not associated with any focal neurologic deficit, a critical feature of SCI. Neuroradiology and neurology committees adjudicated the presence of SCI, which was diagnosed in 30.8% of participants. In a multivariable logistic regression analysis, the following were statistically significantly associated with an increased risk of a SCI: (1) hemoglobin in the lowest quartile, < 7.6 g/dL, compared with the highest quartile, ≥ 8.6 g/dL (OR 2.12, 95% CI 1.45-3.10, P < .001); (2) systolic blood pressure (SBP) in the highest quartile, > 113 mmHg, compared with the lowest quartile, < 104 mmHg (OR 1.73, 95% CI 1.18-2.54, P = .013); and (3) male sex compared with the reference population female sex (OR 1.42, 95% CI 1.04-1.93, P = .026).8 

No established relationship exists between SCI and abnormal TCD measurements or magnetic resonance angiography (MRA) imaging. In the STOP (Stroke Prevention Trial in SCA) Trial, the prevalence of SCI at randomization to regular blood transfusion or standard treatment in those with abnormal TCD was 47 (37%) of 127 patients with SCD and abnormal TCD.42  This is similar to a recent report from France in a single-center population not selected for TCD abnormality.2  In a retrospective study of 78 children with SCA from 5 centers participating in both the CSSCD and the STOP Trial, including 17 children with SCI, Wang et al found no significant statistical relationship between the presence of SCI and abnormal TCD measurements.43  The majority of children with SCI in the context of SCD do not have evidence of cerebral vasculopathy as assessed by MRA of the circle of Willis.44  However, a larger, more systematic, analysis is needed to formally address the relationship between TCD measurements, SCI, and MRA abnormalities.

SCI is believed to be a small vessel disease, although direct evidence supporting this postulate is lacking. In fact, in 9 adults without SCA, but with carotid occlusion, small lesions were identified in the deep white matter, similar in character to SCI and likely to be related to poor cerebrovascular hemodynamic reserve.45  In SCD, focal perfusion abnormalities are common46  and are often, but not always, related to infarction (overt and silent) and cerebrovascular disease. One MR perfusion study included 48 patients, 8 and 14 with overt stroke and SCI, respectively, and 25 with perfusion abnormality. Only 4 patients with small SCI had no detectable perfusion abnormality.46  Studies exploring other reasons for reduced perfusion, including imaging of the heart and neck vessels, are required to exclude cardiac, carotid, or vertebrobasilar occlusive disease as possible mechanisms.47  The predilection for SCI to occur in the border zone areas of the brain suggests that hemodynamic factors could play a role in the pathogenesis.

Regardless of the etiology, chronic anemia is associated with SCI and lower global IQ.17,48,49  Anemia results in hyperemia, hypervolemia, and cerebral vasculature vasodilatation50  to maintain constant cerebral metabolic rate for oxygen. The intrinsic compensatory mechanisms to maintain constant global cerebral blood flow (CBF) are already close to the maximum levels, so any decrease in CBF for physiologic reasons, for example, increased carbon dioxide tension,50,51  compromised cardiac function,52  or increased metabolic demand of the brain tissue, which carries a risk of imbalance between demand and supply of oxygen to the brain. As would be anticipated, children with SCA and acute illness that results in either a decrease in oxygen delivery, such as acute chest syndrome, or an increase in metabolic demands of the brain, such as seizure or fever, would be expected to be at risk for SCI. Dowling et al demonstrated that children with SCA and normal MRA of the brain had evidence of SCI temporally associated with clinical events that included, but were not limited to, acute drops in their hemoglobin secondary to infection, decrease in oxygen delivery secondary to acute chest syndrome, or increase in the metabolic demands of the brain from fever.53  Thus, this small but important case series, along with the recent data demonstrating that baseline low hemoglobin is a risk factor for SCI,2,8  provide proof of principle that an alteration in either the delivery of oxygen (based on a low hemoglobin) or increase in cerebral metabolic demand (Figure 8), may provide sufficient cause for unsuspected SCI that will only be detected with a low threshold to perform brain MRI.54 

Figure 8

Potentially synergistic factors leading to SCI in SCA. Modified from DeBaun et al54  with permission. Equation 1: The CMRO2 is the cerebral metabolic rate for oxygen. The brain relies on a constant delivery of oxygen to maintain CMRO2. If the delivery is inadequate, permanent tissue injury can occur, depending on the depth and duration of the ischemia. The equation above relates cerebral blood flow (CBF; the bulk delivery of blood to the brain), oxygen extraction fraction (OEF; the fraction of available oxygen blood that leaves the blood by passive diffusion as it passes through the circulation), and the arterial oxygen content (CaO2). Equation 2: CaO2, in turn, is a product of the hemoglobin content of blood and the arterial oxygen saturation. Reduced hemoglobin (Hgb; or oxygen carrying capacity of the existing Hgb) or hypoxia may reduce the arterial oxygen content. One can see the potentially synergystic effects of these relationships in reducing the oxygen delivery to the brain below critical thresholds. CaO2 can fall because of anemia and hypoxia and CBF can fall because of the large artery vasculopathy. Patients with preexisting arteriopathy may be more likely to suffer an ischemic stroke than other patients with the same degree of anemia or hypoxia.

Figure 8

Potentially synergistic factors leading to SCI in SCA. Modified from DeBaun et al54  with permission. Equation 1: The CMRO2 is the cerebral metabolic rate for oxygen. The brain relies on a constant delivery of oxygen to maintain CMRO2. If the delivery is inadequate, permanent tissue injury can occur, depending on the depth and duration of the ischemia. The equation above relates cerebral blood flow (CBF; the bulk delivery of blood to the brain), oxygen extraction fraction (OEF; the fraction of available oxygen blood that leaves the blood by passive diffusion as it passes through the circulation), and the arterial oxygen content (CaO2). Equation 2: CaO2, in turn, is a product of the hemoglobin content of blood and the arterial oxygen saturation. Reduced hemoglobin (Hgb; or oxygen carrying capacity of the existing Hgb) or hypoxia may reduce the arterial oxygen content. One can see the potentially synergystic effects of these relationships in reducing the oxygen delivery to the brain below critical thresholds. CaO2 can fall because of anemia and hypoxia and CBF can fall because of the large artery vasculopathy. Patients with preexisting arteriopathy may be more likely to suffer an ischemic stroke than other patients with the same degree of anemia or hypoxia.

Close modal

SCI may result from additional causes beyond hemodynamic insufficiency. Some SCI may result from thromboemboli, for example, related to patent foramen ovale53  or intrapulmonary shunts, although the prevalence of SCI-associated patent foramen ovale is probably similar to that in the general pediatric population.53  The role of other mechanisms, such as posterior reversible encephalopathy syndrome,55  venous sinus thrombosis,56  and demyelination,57  in the development of SCI has not been extensively explored.

Given the observation that SCI are associated with current morbidity, including poor educational attainment26  and future cerebral infarcts,15  evidence-based medical interventions are needed. However, currently no established therapy is available for primary or secondary prevention of SCI.

Children with SCA with both SCI and abnormal TCD are at higher risk of developing an overt stroke42  than those with only an abnormal TCD measurement. In the STOP Trial, comparing participants in the observation arm with both SCI and abnormal TCD measurements versus those with only an abnormal TCD measurement, the rate of a stroke was significantly greater: 52% (15 of 29) compared with 21% (9 of 42; P = .008). These results suggest that the presence of SCI in the setting of an abnormal TCD measurement is associated with increased risk of stroke. In the same study, the investigators demonstrated that blood transfusion therapy attenuated the rate of strokes in the group with both SCI and elevated TCD measurements compared with only elevated TCD measurement, 0% (0 of 18) and 5% (2 of 38) respectively. Twelve patients developed new or enlarged SCI after 36 months of follow-up, only 1 of whom was randomized to transfusion. These results provided preliminary evidence that regular blood transfusion therapy may be effective in preventing neurologic injury and served as strong preliminary data for the SIT Trial.7  In a follow-up study, the results were similar. At the end of STOP2, when children with elevated TCD measurements were randomized to continue or to stop transfusion, 8% of participants who continued transfusion developed new brain MRI lesions compared with 28% who stopped. The total number of lesions decreased from 25 to 24 in the continued-transfusion group while increasing from 27 to 45 in those who stopped.58  Taken together, data from both STOP and STOP2 indicated that children with SCA and both SCI and elevated TCD measurements are at extremely high risk to have progressive SCI. However, we do not know whether children with SCA, SCI, and elevated TCD measurements below the transfusion threshold are at increased risk of SCI and if so, whether the magnitude of the risk outweighs the burden and benefit of regular blood transfusion therapy.

Based on the high prevalence of SCI, the presence of cognitive and educational morbidity, coupled with the progressive nature of SCI, King et al performed a single-arm feasibility study demonstrating that parents were willing to accept blood transfusion therapy as an intervention.59  These results also provided preliminary evidence for the short-term efficacy of blood transfusion therapy to prevent progression of neurologic injury in patients with SCI. Subsequently, the SIT Trial (NCT00072761) was funded.7  The primary hypothesis of the SIT Trial is that children randomly allocated to blood transfusion will have an 86% relative risk reduction of an overt stroke or progressive SCI compared with children randomly allocated to observation.7  A total of 1211 children with SCA between the ages of 5 and 15 years were screened for SCI, of whom 196 were randomly allocated to either arm. The study is fully enrolled; although, a 3-year follow-up is required, thus results from this trial are not expected until after June 2013.

No other systematic strategy for the treatment of SCI has been established. Hydroxyurea and HSCT are potential options for primary and secondary prevention of SCI. There are preliminary data for both therapies in single-arm studies, suggesting efficacy as a secondary preventive strategy for SCI. Two groups have documented that no new SCI have occurred after successfully engrafted HSCT57,60  although one HSCT study documented that new SCI may occur in the immediate posttransplantation period.61  No clinical trial has been undertaken to determine the relative benefits and burden of HSCT as secondary prevention of SCI.

Recently, in a prospective multicenter, single-arm study, Hulbert et al demonstrated that children with overt strokes receiving blood transfusion therapy may still develop new SCI.62  Forty children with overt strokes were followed for ∼ 5 years with surveillance MRI and MRA performed every 1-2 years. The mean pretransfusion hemoglobin S concentration was < 30% throughout the treatment period. Approximately two-thirds of the patients had MRA evidence of cerebral vasculopathy at baseline. Despite the rigorous transfusion regimen, 18% (7 of 40) and 28% (11 of 40) had new overt or SCI, respectively. These data strongly challenge the paradigm that blood transfusion therapy is an optimal therapy for secondary prevention of stroke or SCIs when there is preexisting vasculopathy. Furthermore, for children with overt strokes who are receiving blood transfusion therapy, surveillance MRI of the brain every 1-2 years should be done to assess whether there is progressive neurologic disease because as many as 25% of this population may develop new SCI,62  and alternative therapies, for example, revascularization for moyamoya, might be considered.

Despite the lack of evidence for an established medical treatment for SCI, there is sufficient support that identifying SCI is of clinical benefit to the child with SCA. Screening for SCI is currently performed in selected hematology centers where multidisciplinary teams are evaluating cognitive services and medical interventions, for example, hydroxyurea or HSCT for children with SCA and infarcts of the brain.1,2,63  Based on the high prevalence of SCI, at least 27% before 6 years of age, coupled with the well-established cognitive deficits, performing screening MRI examination in students at least once is a reasonable strategy. Early diagnosis of a SCI in a child with cognitive or behavioral problems may enable teachers to alter strategies and may secure additional education resources to help the student gain the skills necessary for successful academic attainment. Services include, but may not be limited to, occupational therapy, parent counseling, physical therapy, social work services, speech/language pathology, assistive technology, recreation, and counseling services. In the United States, special services are provided in a least restrictive educational setting and are designed specific to the needs of the students through Individual Education Programs (IEPs). Eligibility for special education services is identified by the school through a full evaluation of the child in all areas of suspected disability. If the student is found eligible for services, the school is required to convene the IEP team annually and develop an appropriate plan for the child. The presence of SCI in children with SCA, coupled with significant deficits on cognitive test scores, greatly increases the likelihood of obtaining an IEP in the United States or a statement of educational needs in Europe. Similar strategies, namely assessment of resources for adults with SCI, have not been studied.

Among children with SCA, SCI are prevalent and associated with significant cognitive and academic morbidity. SCI is a distinct clinical entity compared with overt stroke (see Table 1). The natural history and risk factors for SCI are incompletely understood. SCIs occur in infants as young as 1 year of age and continue throughout childhood with the highest incidence rate in children < 6 years of age. The frequency and natural history of new SCI occurring among adults is not well defined. Among individuals with preexisting SCI, there is a significant risk for new SCI or overt strokes compared with individuals without SCI. The only method available to reliably identify SCI is brain MRI. Children with SCD who perform poorly in the classroom or have an acute decline in academic performance should be considered for evaluation for SCI using MRI, a neurologic examination, and cognitive testing. Adults with SCA have at least a one-third chance of having a SCI. Given the high neurologic disease burden, screening and detection of SCI has become standard care where supportive services are readily available. For children with SCA and SCI, an ongoing multicenter international trial will determine whether blood transfusion therapy is an efficacious treatment in preventing further neurologic injury compared with observation.7  Until the results of this trial are known, the use of transfusions should not be considered a standard of care and only considered on a case-by-case basis. Likewise, there is no high-level evidence to support the use of hydroxyurea or HSCT for SCI. Future work should focus on the risk factors and potential primary prevention of SCI, particularly in the highest risk group, young children between infancy and 6 years of age.

Table 1

Clinical characteristics of overt strokes and silent cerebral infarcts in sickle cell anemia

Overt strokesSilent cerebral infarcts
Frequency prior to 6th birthday 2%-5% 27% 
Mean global IQ 71 83 
Primary prevention Transcranial Doppler followed by blood transfusion therapy None established; ongoing limited institution studies of hydroxyurea and HLA-matched sibling transplantation 
Secondary prevention Blood transfusion therapy HLA-matched sibling transplant revascularization for moyamoya None established; await the results of the Silent Cerebral Infarct Transfusion Trial 
Overt strokesSilent cerebral infarcts
Frequency prior to 6th birthday 2%-5% 27% 
Mean global IQ 71 83 
Primary prevention Transcranial Doppler followed by blood transfusion therapy None established; ongoing limited institution studies of hydroxyurea and HLA-matched sibling transplantation 
Secondary prevention Blood transfusion therapy HLA-matched sibling transplant revascularization for moyamoya None established; await the results of the Silent Cerebral Infarct Transfusion Trial 

The authors thank Diana Truran-Sacrey, MD, for initial comments before preparing the manuscript; Mark Roedigher for preparing Figure 5; and Cindy Terrill for manuscript preparation.

This work was supported by funding from the National Institute of Neurological Disorders and Stroke (U01 NS042804; M.R.D.); Burroughs Wellcome Translational Research Award no. 1006671 (M.R.D.); Action Medical Research (F.J.K.); and The Wellcome Trust (0353521/A/92&94/Z and 056325/Z/98; F.J.K.).

National Institutes of Health

Wellcome Trust

Contribution: M.R.D., F.D.A., R.C.M., R.E.W., E.V., and F.J.K. analyzed the data and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Michael R. DeBaun, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232; e-mail: [email protected].

1
Kwiatkowski
 
JL
Zimmerman
 
RA
Pollock
 
AN
et al. 
Silent infarcts in young children with sickle cell disease.
Br J Haematol
2009
, vol. 
146
 
3
(pg. 
300
-
305
)
2
Bernaudin
 
F
Verlhac
 
S
Arnaud
 
C
et al. 
Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort.
Blood
2011
, vol. 
117
 
4
(pg. 
1130
-
1140
quiz 1436
3
Hindmarsh
 
PC
Brozovic
 
M
Brook
 
CG
Davies
 
SC
Incidence of overt and covert neurological damage in children with sickle cell disease.
Postgrad Med J
1987
, vol. 
63
 
743
(pg. 
751
-
753
)
4
Watkins
 
KE
Hewes
 
SKM
Connelly
 
A
et al. 
Cognitive deficits associated with frontal-lobe infarction in children with sickle cell disease.
Dev Med Child Neurol
1998
, vol. 
40
 
8
(pg. 
536
-
543
)
5
Moser
 
FG
Miller
 
ST
Bello
 
JA
et al. 
The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.
Am J Neuroradiol
1996
, vol. 
17
 
5
(pg. 
965
-
972
)
6
Kinney
 
TR
Helms
 
RW
O'Branski
 
EE
et al. 
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Blood
1999
, vol. 
94
 
5
(pg. 
1550
-
1554
)
7
Casella
 
JF
King
 
AA
Barton
 
B
et al. 
Design of the silent cerebral infarct transfusion (SIT) trial.
Pediatr Hematol Oncol
2010
, vol. 
27
 
2
(pg. 
69
-
89
)
8
DeBaun
 
MR
Sarnaik
 
SA
Rodeghier
 
MJ
et al. 
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure [published online ahead of print November 17, 2011].
Blood
 
9
Vichinsky
 
EP
Neumayr
 
LD
Gold
 
JI
et al. 
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia.
JAMA
2010
, vol. 
303
 
18
(pg. 
1823
-
1831
)
10
Zhu
 
YC
Dufouil
 
C
Tzourio
 
C
Chabriat
 
H
Silent brain infarcts: a review of MRI diagnostic criteria.
Stroke
2011
, vol. 
42
 
4
(pg. 
1140
-
1145
)
11
Steen
 
RG
Emudianughe
 
T
Hankins
 
GM
et al. 
Brain imaging findings in pediatric patients with sickle cell disease.
Radiology
2003
, vol. 
228
 
1
(pg. 
216
-
225
)
12
Baldeweg
 
T
Hogan
 
AM
Saunders
 
DE
et al. 
Detecting white matter injury in sickle cell disease using voxel-based morphometry.
Ann Neurol
2006
, vol. 
59
 
4
(pg. 
662
-
672
)
13
Chen
 
R
Pawlak
 
MA
Flynn
 
TB
Krejza
 
J
Herskovits
 
EH
Melhem
 
ER
Brain morphometry and intelligence quotient measurements in children with sickle cell disease.
J Dev Behav Pediatr
2009
, vol. 
30
 
6
(pg. 
509
-
517
)
14
Provenzale
 
JM
Sorensen
 
AG
Diffusion-weighted MR imaging in acute stroke: theoretic considerations and clinical applications.
AJR Am J Roentgenol
1999
, vol. 
173
 
6
(pg. 
1459
-
1467
)
15
Pegelow
 
CH
Macklin
 
EA
Moser
 
FG
et al. 
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease.
Blood
2002
, vol. 
99
 
8
(pg. 
3014
-
3018
)
16
Moser
 
FG
Miller
 
ST
Bello
 
JA
et al. 
The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.
AJNR Am J Neuroradiol
1996
, vol. 
17
 
5
(pg. 
965
-
972
)
17
Bernaudin
 
F
Verlhac
 
S
Freard
 
F
et al. 
Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation.
J Child Neurol
2000
, vol. 
15
 
5
(pg. 
333
-
343
)
18
Zafeiriou
 
DI
Prengler
 
M
Gombakis
 
N
et al. 
Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia.
Ann Neurol
2004
, vol. 
55
 
6
(pg. 
835
-
839
)
19
Kugler
 
S
Anderson
 
B
Cross
 
D
et al. 
Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications.
Arch Neurol
1993
, vol. 
50
 
6
(pg. 
629
-
635
)
20
Manfre
 
L
Giarratano
 
E
Maggio
 
A
Banco
 
A
Vaccaro
 
G
Lagalla
 
R
MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.
AJR Am J Roentgenol
1999
, vol. 
173
 
6
(pg. 
1477
-
1480
)
21
Marouf
 
R
Gupta
 
R
Haider
 
MZ
Adekile
 
AD
Silent brain infarcts in adult Kuwaiti sickle cell disease patients.
Am J Hematol
2003
, vol. 
73
 
4
(pg. 
240
-
243
)
22
Armstrong
 
FD
Thompson
 
RJ
Wang
 
W
et al. 
Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease.
Pediatrics
1996
, vol. 
97
 
6 Pt 1
(pg. 
864
-
870
)
23
Wang
 
WC
Langston
 
JW
Steen
 
RG
et al. 
Abnormalities of the central nervous system in very young children with sickle cell anemia.
J Pediatr
1998
, vol. 
132
 
6
(pg. 
994
-
998
)
24
Wang
 
WC
Pavlakis
 
SG
Helton
 
KJ
et al. 
MRI abnormalities of the brain in one-year-old children with sickle cell anemia.
Pediatr Blood Cancer
2008
, vol. 
51
 
5
(pg. 
643
-
646
)
25
Silva
 
GS
Vicari
 
P
Figueiredo
 
MS
Carrete
 
H
Idagawa
 
MH
Massaro
 
AR
Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler findings.
Stroke
2009
, vol. 
40
 
7
(pg. 
2408
-
2412
)
26
Schatz
 
J
Brown
 
RT
Pascual
 
JM
Hsu
 
L
DeBaun
 
MR
Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease.
Neurology
2001
, vol. 
56
 
8
(pg. 
1109
-
1111
)
27
Schatz
 
J
White
 
DA
Moinuddin
 
A
Armstrong
 
M
DeBaun
 
MR
Lesion burden and cognitive morbidity in children with sickle cell disease.
J Child Neurol
2002
, vol. 
17
 
12
(pg. 
891
-
895
)
28
Wang
 
W
Enos
 
L
Gallagher
 
D
et al. 
Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease.
J Pediatr
2001
, vol. 
139
 
3
(pg. 
391
-
397
)
29
Hogan
 
AM
Kirkham
 
FJ
Prengler
 
M
et al. 
An exploratory study of physiological correlates of neurodevelopmental delay in infants with sickle cell anaemia.
Br J Haematol
2006
, vol. 
132
 
1
(pg. 
99
-
107
)
30
DeBaun
 
MR
Schatz
 
J
Siegel
 
MJ
et al. 
Cognitive screening examinations for silent cerebral infarcts in sickle cell disease.
Neurology
1998
, vol. 
50
 
6
(pg. 
1678
-
1682
)
31
Brown
 
RT
Davis
 
PC
Lambert
 
R
Hsu
 
L
Hopkins
 
K
Eckman
 
J
Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease.
J Pediatr Psychol
2000
, vol. 
25
 
7
(pg. 
503
-
513
)
32
Hogan
 
AM
Pit-ten Cate
 
IM
Vargha-Khadem
 
F
Prengler
 
M
Kirkham
 
FJ
Physiological correlates of intellectual function in children with sickle cell disease: hypoxaemia, hyperaemia and brain infarction.
Dev Sci
2006
, vol. 
9
 
4
(pg. 
379
-
387
)
33
Steen
 
RG
Reddick
 
WE
Mulhern
 
RK
et al. 
Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI.
J Magn Reson Imaging
1998
, vol. 
8
 
3
(pg. 
535
-
543
)
34
White
 
DA
Moinuddin
 
A
McKinstry
 
RC
Noetzel
 
M
Armstrong
 
M
DeBaun
 
M
Cognitive screening for silent cerebral infarction in children with sickle cell disease.
J Pediatr Hematol Oncol
2006
, vol. 
28
 
3
(pg. 
166
-
169
)
35
Steen
 
RG
Miles
 
MA
Helton
 
KJ
et al. 
Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit.
AJNR Am J Neuroradiol
2003
, vol. 
24
 
3
(pg. 
382
-
389
)
36
White
 
DA
Salorio
 
CF
Schatz
 
J
DeBaun
 
M
Preliminary study of working memory in children with stroke related to sickle cell disease.
J Clin Exp Neuropsychol
2000
, vol. 
22
 
2
(pg. 
257
-
264
)
37
Schatz
 
J
Craft
 
S
Koby
 
M
et al. 
Neuropsychologic deficits in children with sickle cell disease and cerebral infarction: The role of lesion site and volume.
J Child Neuropsychol
1999
, vol. 
5
 
2
(pg. 
92
-
103
)
38
Schatz
 
J
Buzan
 
R
Decreased corpus callosum size in sickle cell disease: relationship with cerebral infarcts and cognitive functioning.
J Int Neuropsychol Soc
2006
, vol. 
12
 
1
(pg. 
24
-
33
)
39
Rothman
 
SM
Fulling
 
KH
Sickle cell anemia and central nervous system infarction: a neuropathological study.
Ann Neurol
1986
, vol. 
20
 (pg. 
684
-
690
)
40
Koshy
 
M
Thomas
 
C
Goodwin
 
J
Vascular lesions in the central nervous system in sickle cell disease (neuropathology).
J Assoc Acad Minor Phys
1990
, vol. 
1
 
3
(pg. 
71
-
78
)
41
Kimmelsteil
 
P
Vascular occlusion and ischemic infarction in sickle cell disease.
Am J Med Sci
1948
, vol. 
216
 
1
(pg. 
11
-
19
)
42
Pegelow
 
CH
Wang
 
W
Granger
 
S
et al. 
Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity.
Arch Neurol
2001
, vol. 
58
 
12
(pg. 
2017
-
2021
)
43
Wang
 
WC
Gallagher
 
DM
Pegelow
 
CH
et al. 
Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease.
J Pediatr Hematol Oncol
2000
, vol. 
22
 
4
(pg. 
335
-
339
)
44
Thangarajh
 
M
Fuchs
 
D
Ponision
 
R
et al. 
Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts in children with sickle cell anemia.
61st Annual American Academy of Neurology
April 25-May 2, 2009
Seattle, WA
45
Waterston
 
JA
Brown
 
MM
Butler
 
P
Swash
 
M
Small deep cerebral infarcts associated with occlusive internal carotid artery disease: a hemodynamic phenomenon?
Arch Neurol
1990
, vol. 
47
 
9
(pg. 
953
-
957
)
46
Kirkham
 
FJ
Calamante
 
F
Bynevelt
 
M
et al. 
Perfusion magnetic resonance abnormalities in patients with sickle cell disease.
Ann Neurol
2001
, vol. 
49
 
4
(pg. 
477
-
485
)
47
Telfer
 
PT
Evanson
 
J
Butler
 
P
et al. 
Cervical carotid artery disease in sickle cell disease: clinical and radiological features.
Blood
2011
, vol. 
118
 
23
(pg. 
6192
-
6199
)
48
Zafeiriou
 
DI
Prengler
 
M
Pavlakis
 
S
Kirkham
 
FJ
Ganesan
 
V
Kirkham
 
F
Congenital and acquired anaemias.
Stroke and Cerebrovascular Disease in Childhood–International Review of Child Neurology
2011
London, United Kingdom
Mac Keith Press
49
Kobayashi
 
S
Ikeda
 
T
Moriya
 
H
Ohtake
 
T
Kumagai
 
H
Asymptomatic cerebral lacunae in patients with chronic kidney disease.
Am J Kidney Dis
2004
, vol. 
44
 
1
(pg. 
35
-
41
)
50
Prohovnik
 
I
Hurlet-Jensen
 
A
Adams
 
R
De Vivo
 
D
Pavlakis
 
SG
Hemodynamic etiology of elevated flow velocity and stroke in sickle-cell disease.
J Cereb Blood Flow Metab
2009
, vol. 
29
 
4
(pg. 
803
-
810
)
51
Kedar
 
A
Drane
 
WE
Shaeffer
 
D
Nicole
 
M
Adams
 
C
Measurement of cerebrovascular flow reserve in pediatric patients with sickle cell disease.
Pediatr Blood Cancer
2006
, vol. 
46
 
2
(pg. 
234
-
238
)
52
Johnson
 
MC
Kirkham
 
FJ
Redline
 
S
et al. 
Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation.
Blood
2010
, vol. 
116
 
1
(pg. 
16
-
21
)
53
Dowling
 
MM
Quinn
 
CT
Rogers
 
ZR
Buchanan
 
GR
Acute silent cerebral infarction in children with sickle cell anemia.
Pediatr Blood Cancer
2010
, vol. 
54
 
3
(pg. 
461
-
464
)
54
DeBaun
 
MR
Derdeyn
 
CP
McKinstry
 
RC
Etiology of strokes in children with sickle cell anemia.
Ment Retard Dev Disabil Res Rev
2006
, vol. 
12
 
3
(pg. 
192
-
199
)
55
Henderson
 
JN
Noetzel
 
MJ
McKinstry
 
RC
White
 
DA
Armstrong
 
M
DeBaun
 
MR
Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease.
Blood
2003
, vol. 
101
 
2
(pg. 
415
-
419
)
56
Sebire
 
G
Tabarki
 
B
Saunders
 
DE
et al. 
Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome.
Brain
2005
, vol. 
128
 
Pt 3
(pg. 
477
-
489
)
57
Walters
 
MC
Hardy
 
K
Edwards
 
S
et al. 
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.
Biol Blood Marrow Transplant
2010
, vol. 
16
 
2
(pg. 
263
-
272
)
58
Abboud
 
MR
Yim
 
E
Musallam
 
KM
Adams
 
RJ
Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II.
Blood
2011
, vol. 
118
 
4
(pg. 
894
-
898
)
59
King
 
AA
White
 
DA
McKinstry
 
RC
Noetzel
 
M
Debaun
 
MR
A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes.
Neurology
2007
, vol. 
68
 
23
(pg. 
2008
-
2011
)
60
Bernaudin
 
F
Socie
 
G
Kuentz
 
M
et al. 
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.
Blood
2007
, vol. 
110
 
7
(pg. 
2749
-
2756
)
61
Woodard
 
P
Helton
 
KJ
Khan
 
RB
et al. 
Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease.
Br J Haematol
2005
, vol. 
129
 
4
(pg. 
550
-
552
)
62
Hulbert
 
ML
McKinstry
 
RC
Lacey
 
JL
et al. 
Silent cerebral infarcts occur despite regular blood transfusion therapy after first stroke in children with sickle cell disease.
Blood
2011
, vol. 
117
 
3
(pg. 
772
-
779
)
63
King
 
A
Herron
 
S
McKinstry
 
R
et al. 
A multidisciplinary health care team's efforts to improve educational attainment in children with sickle-cell anemia and cerebral infarcts.
J Sch Health
2006
, vol. 
76
 
1
(pg. 
33
-
37
)
64
Thompson
 
RJ
Link
 
CL
Pegelow
 
CH
Moser
 
F
Wang
 
WC
A prospective study of the relationship over time of behavior problems, intellectual functioning, and family functioning in children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease.
J Pediatr Psychol
2003
, vol. 
28
 
1
(pg. 
59
-
65
)
65
Steen
 
RG
Fineberg-Buchner
 
C
Hankins
 
G
Weiss
 
L
Prifitera
 
A
Mulhern
 
RK
Cognitive deficits in children with sickle cell disease.
J Child Neurol
2005
, vol. 
20
 
2
(pg. 
102
-
107
)
Sign in via your Institution